Tocilizumab, Drugs Monitor, Page 9

(26 May 2020) Tocilizumab- rapid beneficial effect on fever and inflammatory markers

May 27, 2020

Off-label use of tocilizumab for the treatment of SARS-CoV-2 pneumonia in Milan, Italy https://doi.org/10.1016/j.ejim.2020.05.011 In this open-label prospective study clinical characteristics and outcome of 51 patients hospitalized with confirmed and severe COVID-19 pneumonia treated with tocilizumab are described. Forty-five patients… Continue reading "(26 May 2020) Tocilizumab- rapid beneficial effect on fever and inflammatory markers"

(25 May 2020) Hydroxychloroquine & Tocilizumab- HCQ no survival benefit, TCZ improved survival

May 25, 2020

Hydroxychloroquine and Tocilizumab Therapy in COVID-19 Patients – An Observational Study https://doi.org/10.1101/2020.05.21.20109207 Among 2512 hospitalized patients with COVID-19 there have been 547 deaths (22%), 1539 (61%) discharges and 426 (17%) remain hospitalized. 1914 (76%) received at least one dose of… Continue reading "(25 May 2020) Hydroxychloroquine & Tocilizumab- HCQ no survival benefit, TCZ improved survival"

(19 May 2020) Tocilizumab- may offer short-term survival benefit in severe ill patients

May 20, 2020

Off-Label Real World Experience Using Tocilizumab for Patients Hospitalized with COVID-19 Disease in a Regional Community Health System: A Case-Control Study https://doi.org/10.1101/2020.05.14.20099234 In an observational study, among 86 patients, 21 received Tocilizumab during the hospital stay. Both the Cox model… Continue reading "(19 May 2020) Tocilizumab- may offer short-term survival benefit in severe ill patients"

(16 May 2020) Tocilizumab- Higher survival rate and outcome

May 18, 2020

Improved survival outcome in SARs-CoV-2 (COVID-19) Acute Respiratory Distress Syndrome patients with Tocilizumab administration https://doi.org/10.1101/2020.05.13.20100081 A total of 94 patients with COVID-19 ARDS were analyzed. 44 were in the study group and 50 in the control group. Average HS score… Continue reading "(16 May 2020) Tocilizumab- Higher survival rate and outcome"

(12 May 2020) Tocilizumab- onset to tocilizumab administration may be critical to patient recovery

May 13, 2020

(12 May 2020) Tocilizumab- onset to tocilizumab administration may be critical to patient recovery Early outcomes of tocilizumab in adults hospitalized with severe COVID-19 – 2 SUBTITLE: An initial report from the Vall d’Hebron COVID-19 prospective cohort 3 study. https://doi.org/10.1101/2020.05.07.20094599… Continue reading "(12 May 2020) Tocilizumab- onset to tocilizumab administration may be critical to patient recovery"

(11 May 2020) Tocilizumab- reduced ICU admissions and deaths

May 12, 2020

Tocilizumab therapy reduced intensive care unit admissions and/ormortality in COVID-19 patients https://doi.org/doi:10.1016/j.medmal.2020.05.001 In a retrospective case-control study with a small sample size, death and/or ICU admissions were higher in patients without Tocilizumab (TCZ) than in the TCZ group (72% vs… Continue reading "(11 May 2020) Tocilizumab- reduced ICU admissions and deaths"

(04 May 2020) Tocilizumab- reduced effects of Tocilizumab in hyperglycemic patients

May 5, 2020

Negative impact of hyperglycemia on Tocilizumab therapy in COVID-19 patients https://www.medrxiv.org/content/10.1101/2020.04.29.20076570v1 During a retrospective study on 475 Covid-19 positive patients, 78 patients with pneumonia disease and treated with tocilizumab were further evaluated for a severe outcome (encompassing both the use… Continue reading "(04 May 2020) Tocilizumab- reduced effects of Tocilizumab in hyperglycemic patients"

(01 May 2020) Tocilizumab- reduced mortality in severe COVID 19 patients

May 5, 2020

Effective treatment of severe COVID-19 patients with tocilizumab https://doi.org/10.1073/pnas.2005615117 This is a retrospective study on tocilizumab, an IL6R inhibitor, in treatment of 21 patients with severe and critical COVID-19. Within 5 days after tocilizumab, 15 of the 20 patients (75.0%)… Continue reading "(01 May 2020) Tocilizumab- reduced mortality in severe COVID 19 patients"

(27 April 2020) Update on clinical studies of key drug molecules for COVID 19

April 28, 2020

Update on treatment of COVID-19: ongoing studies between promising and disappointing results. https://www.ncbi.nlm.nih.gov/pubmed/32335561 A compilation of results of trials going on (up to April 15, 2020)for key molecules used in treatment of COVID-19 is presented. Data for Chloroquine, hydroxychloroquine, remdesevir,… Continue reading "(27 April 2020) Update on clinical studies of key drug molecules for COVID 19"

(22 April 2020) Tocilizumab- within 24 h following the tocilizumab infusion, improvement in fever and hypoxaemia observed

April 27, 2020

Case study : a patient with asthma, Covid-19 pneumonia and cytokine release syndrome treated with corticosteroids and tocilizumab https://journals.co.za/content/journal/10520/EJC-1c8cd2727d#abstract_content This report elaborates case of a patient with Covid-19 infection, progressive pneumonia, development of a hyperinflammatory state and cytokine release syndrome… Continue reading "(22 April 2020) Tocilizumab- within 24 h following the tocilizumab infusion, improvement in fever and hypoxaemia observed"

Tag: Tocilizumab